Close Menu

CHICAGO – Nucleai, a developer of a bioinformatics platform for precision oncology research and clinical decision support, may be a startup, but its technology has been proven over more than two decades.

CEO Avi Veidman and several colleagues started the company in 2017. He previously spent nearly 20 years in Israeli military intelligence, where he led a department that applied artificial intelligence and machine learning to the analysis of satellite and aerial images. Eventually, he decided that he wanted to establish a company at the nexus of big data and biology.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.